Correspondence 0001193125-23-219080 from CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc.
Date: Aug. 23, 2023 · CIK: 0001501989 · Accession: 0001193125-23-219080
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274010
Letter
Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jimmy McNamara Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 Filed August 16, 2023 Registration No. 333-274010
Dear Mr. McNamara:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, CytomX Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on August 25, 2023, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please contact Mark V. Roeder of Latham & Watkins LLP, counsel to the Company, at (650) 463-3043, or in his absence, John C. Williams of Latham & Watkins LLP at (415) 395-8223, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Thank you for your assistance in this matter.
* * * *
Sincerely,
CytomX Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP CytomX Therapeutics, Inc. 151 Oyster Point Blvd., Suite 400 South San Francisco, California 94080 August 23, 2023 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: CytomX Therapeutics, Inc. Registration Statement on Form S-3 Filed August 16, 2023 Registration No. 333-274010 Dear Mr. McNamara: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, CytomX Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on August 25, 2023, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please contact Mark V. Roeder of Latham & Watkins LLP, counsel to the Company, at (650) 463-3043, or in his absence, John C. Williams of Latham & Watkins LLP at (415) 395-8223, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Thank you for your assistance in this matter. * * * * Sincerely, CytomX Therapeutics, Inc. By: /s/ Lloyd A. Rowland Lloyd A. Rowland General Counsel cc: Sean A. McCarthy, CytomX Therapeutics, Inc. Christopher W. Ogden, CytomX Therapeutics, Inc. Mark V. Roeder, Latham & Watkins LLP John C. Williams, Latham & Watkins LLP